FDA approves breakthrough daily pill for cholesterol

The FDA recently approved Lipfendra, a new daily pill from Merck designed to lower cholesterol. This drug, also known as enlicitide, represents the first oral version of a PCSK9 inhibitor. Previously, patients needing this class of medication had to rely on injections administered every two weeks.

Health experts view this shift as a significant change in how doctors treat high cholesterol. While injectable options are effective, they are often avoided by patients. Providing a daily oral alternative gives patients more control over their treatment plan. Clinical trials indicate that Lipfendra can reduce bad cholesterol levels by between 56% and 59% when taken alongside standard statins, diet, and exercise.

High cholesterol remains a primary driver of heart disease, which continues to be the leading cause of death in the United States. Buildups in the arteries develop over decades and increase the risk of heart attacks and strokes. By making treatment more accessible, medical professionals hope to reach more people who need intervention to manage their cardiovascular health.

The medication is expected to be available to patients within weeks. The list price is set at $10.50 per day, with officials suggesting that out-of-pocket costs for many will be lower depending on insurance coverage.